Diagnosis and Staging of Multiple Myeloma and Related Disorders

S Vincent Rajkumar, Rafael Fonseca, Jesus F. San Miguel

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Multiple myeloma is a plasma cell neoplasm that predominantly occurs in the elderly, which has preceding benign stages, the so-called MGUS and smoldering myeloma. The precise definition of the various stages of the plasma cell neoplasms is critical to decide when therapy initiation is indicated. Traditionally, therapy was started when patients had overt evidence of end-organ damage, best remembered by the acronym CRAB. Clinical features included evidence of bone destruction, hypercalcemia, renal insufficiency, or anemia. More recently the International Myeloma Working Group has reclassified high-risk smoldering myeloma patients, at high risk of progression (80% at 2 years), as active myeloma and in need of therapy. The three expanded criteria include extreme deviation in the serum free light chain ratio (FLC ratio ≥100, with a minimal involved FLC level of at least 100 mg/L), two or more lesions on MRI, and also an extreme plasmacytosis (≥60%). These criteria allow us to initiate therapy before end-organ damage hopefully preventing long-lasting complications for patients. In addition to the standard clinical criteria, physicians should test for the genetic subtypes of the disease. Understanding the various genetic subtypes has allowed for a better prognostic categorization of patients and most recently has allowed for the development of specific therapeutic approaches for subsets of the disease.

Original languageEnglish (US)
Title of host publicationHematologic Malignancies
PublisherSpringer Verlag
Pages17-28
Number of pages12
Edition9783319255842
DOIs
StatePublished - Jan 1 2018

Publication series

NameHematologic Malignancies
Number9783319255842
ISSN (Print)2197-9766
ISSN (Electronic)2197-9774

Fingerprint

Multiple Myeloma
Plasma Cell Neoplasms
Therapeutics
Inborn Genetic Diseases
Hypercalcemia
Renal Insufficiency
Anemia
Physicians
Light
Bone and Bones
Serum

Keywords

  • Genetics
  • MGUS
  • Myeloma
  • Prognosis
  • Smoldering myeloma

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Rajkumar, S. V., Fonseca, R., & San Miguel, J. F. (2018). Diagnosis and Staging of Multiple Myeloma and Related Disorders. In Hematologic Malignancies (9783319255842 ed., pp. 17-28). (Hematologic Malignancies; No. 9783319255842). Springer Verlag. https://doi.org/10.1007/978-3-319-25586-6_2

Diagnosis and Staging of Multiple Myeloma and Related Disorders. / Rajkumar, S Vincent; Fonseca, Rafael; San Miguel, Jesus F.

Hematologic Malignancies. 9783319255842. ed. Springer Verlag, 2018. p. 17-28 (Hematologic Malignancies; No. 9783319255842).

Research output: Chapter in Book/Report/Conference proceedingChapter

Rajkumar, SV, Fonseca, R & San Miguel, JF 2018, Diagnosis and Staging of Multiple Myeloma and Related Disorders. in Hematologic Malignancies. 9783319255842 edn, Hematologic Malignancies, no. 9783319255842, Springer Verlag, pp. 17-28. https://doi.org/10.1007/978-3-319-25586-6_2
Rajkumar SV, Fonseca R, San Miguel JF. Diagnosis and Staging of Multiple Myeloma and Related Disorders. In Hematologic Malignancies. 9783319255842 ed. Springer Verlag. 2018. p. 17-28. (Hematologic Malignancies; 9783319255842). https://doi.org/10.1007/978-3-319-25586-6_2
Rajkumar, S Vincent ; Fonseca, Rafael ; San Miguel, Jesus F. / Diagnosis and Staging of Multiple Myeloma and Related Disorders. Hematologic Malignancies. 9783319255842. ed. Springer Verlag, 2018. pp. 17-28 (Hematologic Malignancies; 9783319255842).
@inbook{ac84d8645ca943dc8f11fce348d4e8c7,
title = "Diagnosis and Staging of Multiple Myeloma and Related Disorders",
abstract = "Multiple myeloma is a plasma cell neoplasm that predominantly occurs in the elderly, which has preceding benign stages, the so-called MGUS and smoldering myeloma. The precise definition of the various stages of the plasma cell neoplasms is critical to decide when therapy initiation is indicated. Traditionally, therapy was started when patients had overt evidence of end-organ damage, best remembered by the acronym CRAB. Clinical features included evidence of bone destruction, hypercalcemia, renal insufficiency, or anemia. More recently the International Myeloma Working Group has reclassified high-risk smoldering myeloma patients, at high risk of progression (80{\%} at 2 years), as active myeloma and in need of therapy. The three expanded criteria include extreme deviation in the serum free light chain ratio (FLC ratio ≥100, with a minimal involved FLC level of at least 100 mg/L), two or more lesions on MRI, and also an extreme plasmacytosis (≥60{\%}). These criteria allow us to initiate therapy before end-organ damage hopefully preventing long-lasting complications for patients. In addition to the standard clinical criteria, physicians should test for the genetic subtypes of the disease. Understanding the various genetic subtypes has allowed for a better prognostic categorization of patients and most recently has allowed for the development of specific therapeutic approaches for subsets of the disease.",
keywords = "Genetics, MGUS, Myeloma, Prognosis, Smoldering myeloma",
author = "Rajkumar, {S Vincent} and Rafael Fonseca and {San Miguel}, {Jesus F.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/978-3-319-25586-6_2",
language = "English (US)",
series = "Hematologic Malignancies",
publisher = "Springer Verlag",
number = "9783319255842",
pages = "17--28",
booktitle = "Hematologic Malignancies",
address = "Germany",
edition = "9783319255842",

}

TY - CHAP

T1 - Diagnosis and Staging of Multiple Myeloma and Related Disorders

AU - Rajkumar, S Vincent

AU - Fonseca, Rafael

AU - San Miguel, Jesus F.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Multiple myeloma is a plasma cell neoplasm that predominantly occurs in the elderly, which has preceding benign stages, the so-called MGUS and smoldering myeloma. The precise definition of the various stages of the plasma cell neoplasms is critical to decide when therapy initiation is indicated. Traditionally, therapy was started when patients had overt evidence of end-organ damage, best remembered by the acronym CRAB. Clinical features included evidence of bone destruction, hypercalcemia, renal insufficiency, or anemia. More recently the International Myeloma Working Group has reclassified high-risk smoldering myeloma patients, at high risk of progression (80% at 2 years), as active myeloma and in need of therapy. The three expanded criteria include extreme deviation in the serum free light chain ratio (FLC ratio ≥100, with a minimal involved FLC level of at least 100 mg/L), two or more lesions on MRI, and also an extreme plasmacytosis (≥60%). These criteria allow us to initiate therapy before end-organ damage hopefully preventing long-lasting complications for patients. In addition to the standard clinical criteria, physicians should test for the genetic subtypes of the disease. Understanding the various genetic subtypes has allowed for a better prognostic categorization of patients and most recently has allowed for the development of specific therapeutic approaches for subsets of the disease.

AB - Multiple myeloma is a plasma cell neoplasm that predominantly occurs in the elderly, which has preceding benign stages, the so-called MGUS and smoldering myeloma. The precise definition of the various stages of the plasma cell neoplasms is critical to decide when therapy initiation is indicated. Traditionally, therapy was started when patients had overt evidence of end-organ damage, best remembered by the acronym CRAB. Clinical features included evidence of bone destruction, hypercalcemia, renal insufficiency, or anemia. More recently the International Myeloma Working Group has reclassified high-risk smoldering myeloma patients, at high risk of progression (80% at 2 years), as active myeloma and in need of therapy. The three expanded criteria include extreme deviation in the serum free light chain ratio (FLC ratio ≥100, with a minimal involved FLC level of at least 100 mg/L), two or more lesions on MRI, and also an extreme plasmacytosis (≥60%). These criteria allow us to initiate therapy before end-organ damage hopefully preventing long-lasting complications for patients. In addition to the standard clinical criteria, physicians should test for the genetic subtypes of the disease. Understanding the various genetic subtypes has allowed for a better prognostic categorization of patients and most recently has allowed for the development of specific therapeutic approaches for subsets of the disease.

KW - Genetics

KW - MGUS

KW - Myeloma

KW - Prognosis

KW - Smoldering myeloma

UR - http://www.scopus.com/inward/record.url?scp=85042287071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042287071&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-25586-6_2

DO - 10.1007/978-3-319-25586-6_2

M3 - Chapter

T3 - Hematologic Malignancies

SP - 17

EP - 28

BT - Hematologic Malignancies

PB - Springer Verlag

ER -